EXICURE, INC. Debt Securities, Available-for-sale, Realized Loss
EXICURE, INC. (XCUR) reported Debt Securities, Available-for-sale, Realized Loss of $0 for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-19.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2022-03-25
- EXICURE, INC. debt securities, available-for-sale, realized loss for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- EXICURE, INC. debt securities, available-for-sale, realized loss for the quarter ending 2020-12-31 was $0.00.
- EXICURE, INC. debt securities, available-for-sale, realized loss for the quarter ending 2020-09-30 was $6.00K.
- EXICURE, INC. debt securities, available-for-sale, realized loss for the quarter ending 2020-06-30 was $6.00K.
- EXICURE, INC. debt securities, available-for-sale, realized loss for fiscal 2020 was $6.00K.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-19 | $0.00 10-Q · filed 2021-11-19 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $6.00K derived: sum of 2 quarters · filed 2022-03-25 | $12.00K derived: sum of 3 quarters · filed 2022-03-25 | $6.00K 10-K · filed 2022-03-25 |
| 2020-09-30 | $6.00K 10-Q · filed 2020-11-12 | $12.00K derived: sum of 2 quarters · filed 2020-11-12 | $6.00K 10-Q · filed 2021-11-19 | |
| 2020-06-30 | $6.00K 10-Q · filed 2020-08-12 | $6.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |